




EVA PHARMA

# EVA Pharma EU-CTD List 2023



INN	Dosage	Pharmaceutical Form	Indication	Dossier Availability
<b>Alimentary tract &amp; metabolism</b>				
Ondansetron	4 mg, 8 mg	Ampoules	Antiemetic	Available
<b>Anti-Infectives</b>				
Moxifloxacin HCl	400 mg	Tablets	Antibiotic	Available
<b>Cardiovascular System</b>				
Perindopril + Amlodipine + Indapamide	5 + 1.25 + 5 mg 5 + 1.25 + 10 mg 10 + 2.5 + 5 mg 10 + 2.5 + 10 mg	Tablets	Hypertension	Q1 2025
Riociguat	0.5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg	Tablets	Hypertension	Q4 2025
Tolvaptan	15mg, 30mg, 45mg, 60mg, 90 mg	Tablets	Chronic Kidney Disease	Under Development
<b>Endocrine System</b>				
Alogliptin	6.25 mg , 12.5 mg, 25 mg	Tablets	Diabetes Type II	Available
Dapagliflozin + Metformin	5+ 500 mg 5+ 850 mg 5+ 1,000 mg 10+ 500 mg 10+ 1,000 mg	XR Tablets	Diabetes Type II	Q4 2025
Empagliflozin	25mg, 10mg	Tablets	Diabetes Type II	Q3 2024
Empagliflozin + Metformin	5+ 500 mg 5+ 850 mg 5+ 1,000 mg 12.5+ 500 mg 12.5 +850mg 10+ 1,000 mg	Tablets	Diabetes Type II	Q3 2025
Linagliptin	5 mg	Tablets	Diabetes Type II	Q2 2024
Linagliptin + Metformin	2.5+ 850 mg 2.5+ 1000 mg	Tablets	Diabetes Type II	Q3 2024
Vildagliptin	50 mg	Tablets	Diabetes Type II	Available
<b>Musculo-skeletal system</b>				
Ataluren	125 mg, 250 mg, 1,000mg	Granules for oral suspension	Duchenne Muscular Dystrophy	Under Development
Diclofenac Sodium	140 mg / 10 cm x 14 cm Patch	Transdermal Patch	Anti-inflammatory	Q1 2024
Flurbiprofen	40 mg	Transdermal Patch	Anti-inflammatory	Under Development
Lidocaine	700 mg / 10 cm x 14 cm Patch	Transdermal Patch	Anesthetics	Q4 2023
Lidocaine	1%, 2% / 2 ml, 5 ml	Ampoules	Anesthetics	Q1 2024

<b>INN</b>	<b>Dosage</b>	<b>Pharmaceutical Form</b>	<b>Indication</b>	<b>Dossier Availability</b>
<b>Nervous System</b>				
Buspirone HCl	5 mg, 10 mg	Tablets	Anxiolytic	Available
Piribedil	50 mg	XR Tablets	Parkinson disease	Q4 2023
Pyridostigmine Bromide	60 mg	Tablets	Myasthenia gravis	Available
Rotigotine	1 mg, 2mg, 3 mg, 4 mg, 6 mg, 8 mg	Transdermal Patch	Parkinson disease	Q4 2023
Thioctic Acid	600 mg	Tablets	Polyneuropathy	Available
Vortioxetine	5 mg , 10 mg, 15 mg, 20 mg	Tablets	Antidepressant	Q2 2025
<b>Ophthalmology</b>				
Epinastine	0.5 mg/ ml 5 ml multidose	Eye Drops	Conjunctivitis	Under Development
Moxifloxacin	0.5% – 5 ml multidose	Eye Drops	Conjunctivitis	Under Development
<b>Rheumatology</b>				
Febuxostat	80mg	Tablets	Anti-gout	Available
<b>Urology/ Andrology</b>				
Mirabegron	25 mg, 50 mg	Tablets	Overactive Bladder	Q4 2026
Sildenafil	4 mg, 8 mg	Capsules	BPH	Available
Solifenacin + Mirabegron	10 mg + 25 mg 10 mg + 50 mg 5 mg + 25 mg 5 mg + 50 mg	Tablets	Overactive Bladder	Q2 2025
Solifenacin + Tamsulosin	6 mg + 0.4 mg	SR Tablet	BPH	Available
Trospium	20 mg	Tablets	Overactive Bladder	Available
Tadalafil	20 mg	Tablets	Erectile Dysfunction	Available
Vardenafil	20 mg	Tablets	Erectile Dysfunction	Available
<b>Respiratory System</b>				
Indacaterol maleate + Glycopyrronium bromide	85 + 43 mcg	DPI	COPD	Q2 2026
Tiotropium Bromide	18 mcg	DPI	COPD	Available

This list reflects the development status of EVA Pharma. Products protected by valid patents are neither manufactured, nor offered for sale nor marketed in jurisdictions where such activities constitute patent infringement.

This list contains information only and does not constitute any offer.

Visionary Minds,  
Diverse Solutions.

[bd@evapharma.com](mailto:bd@evapharma.com)